Adelaide-headquartered Chrysos Corporation Ltd (ASX: C79) has finalised a three-year, A$200 million syndicated debt facility with Australia and New Zealand Banking Group Limited, National Australia Bank Limited, and Export Finance Australia.
The announcement marks a significant structural shift in how the Company finances its global fleet of PhotonAssay units.
The old facility was asset-based. This one is not. That distinction matters more than it might first appear.
What the $200 Million Debt Facility Actually Changes for Chrysos Corporation
Asset-based financing ties capital availability directly to the value of specific physical assets. Corporate-style facilities work differently.
They give the borrower flexibility to allocate capital across operations, manufacturing, and geography without the constraints baked into asset-level security structures.
For Chrysos, that flexibility comes at a better price. The new facility offers more favourable debt pricing, a reduced commitment fee on undrawn funds, and improved covenant terms compared with what was in place before.
It also adds A$105 million in additional headroom above the existing facility.
The facility includes both a term loan and a revolving component. An accordion mechanism allows further commitments to be added, subject to agreed terms.
Security will be granted by the Company and a number of subsidiaries across Australia, Canada, New Zealand, the United Kingdom, and the United States, with room to bring additional jurisdictions in over time.
Managing Director and CEO Dirk Treasure described the facility as giving Chrysos the capital support required to scale deployments and maintain momentum as customer adoption strengthens.
PhotonAssay Is Replacing a 2,000-Year-Old Method — and the Order Book Shows It
PhotonAssay is not a marginal improvement over fire assay. It is a faster, non-destructive, environmentally cleaner method of analysing gold, silver, copper, and other elements.
Fire assay, which involves heating ore samples to extreme temperatures, has been the industry standard for roughly two millennia. Chrysos is in the business of replacing it.
The forward order book as of 4 June 2026 extends to 22 further PhotonAssay units, plus 27 long-lead components already in procurement.
With the new facility in place, Chrysos is targeting a return to its manufacturing cadence of 18 units per year, a pace that had previously been constrained by capital structure rather than demand.
Four new lease agreements have been signed since the Company’s last update, bringing year-to-date contract signings to 23. Among those new agreements: an expansion with SGS across a growing global footprint, and a second PhotonAssay unit for ALS in Saudi Arabia.
That one is notable given Chrysos is already deployed at some of the world’s largest mining operations across North America and Africa.
During May 2026, Chrysos achieved its third consecutive month of processing more than one million samples. Two units are currently being deployed across two separate regions.
Three Lenders, One Clear Signal from the Market
ANZ, NAB, and Export Finance Australia are not a speculative syndicate. Their collective participation reflects the quality of Chrysos’ revenue profile: long-term committed lease agreements with tier-one mining laboratories and gold producers, underpinned by take-or-pay arrangements that provide meaningful revenue visibility.
Chrysos posted A$66.1 million in revenue for FY2025, up 46% on the prior year. EBITDA grew 80%, and sample volumes rose 75% in the final quarter of calendar year 2025 year-on-year, according to Goldman Sachs’ real-time activity tracker, which initiated coverage with a Buy rating in late 2025.
The company has captured around 5% of its estimated total addressable market.
For a company at this stage of adoption, having three domestic financial institutions willing to underwrite $200 million at corporate-style terms is an endorsement of the business model.
| Feature | Old Facility | New $200M Facility |
|---|---|---|
| Facility Type | Asset-based financing | Corporate-style syndicated facility |
| Debt Pricing | Higher rate | More favourable pricing ✅ |
| Commitment Fee on Undrawn Funds | Higher fee | Reduced commitment fee ✅ |
| Covenant Terms | Standard asset-based covenants | Improved covenant package ✅ |
| Funding Headroom | Base level | Increased by AUD $105 million ✅ |
| Lenders | Single/existing financier(s) | ANZ, NAB, Export Finance Australia |
| Facility Structure | Asset-level security | Term + revolving facility with accordion mechanism ✅ |
| Geographic Flexibility | Limited | Australia, Canada, NZ, UK, USA + additional jurisdictions ✅ |
What FY26 and Beyond Could Look Like
The forward order book of 22 units, combined with 27 long-lead components already secured, gives Chrysos a production pipeline that extends well into FY27.
The Company has previously stated it expects to reach positive net income as deployments scale and unit economics improve with larger fleet size.
Analysts who follow C79 closely have projected earnings of around A$30.5 million by approximately 2028. The current trajectory of contract signings and the structural shift to corporate-style debt suggest those targets have become more credible in 2026 than they appeared even twelve months ago.
The gold price is helping things too. The price of spot gold has stayed high all through 2025 and into 2026. This means more gold samples are being tested, and big labs and mining companies are feeling a bigger push to improve how they analyze things.
A higher gold price means more drilling. More drilling means more samples. More samples means PhotonAssay units are busier, and the economics of leasing versus fire assay analysis improve further in Chrysos’ favour.
Also Read: Oil Hits New Highs – And Australian Petrol Prices Are About to Feel It
Frequently Asked Questions
Q: What is Chrysos Corporation’s new debt facility?
A: Chrysos Corporation got a three-year loan for A$200 million to help them build PhotonAssay
Q: Who invested in the Chrysos debt facility?
A: The investors are Australia and New Zealand Banking Group Limited, National Australia Bank Limited, and Export Finance Australia..
Q: How is the new debt facility different from the old one?
A: Instead of being tied to specific assets, it’s a general company loan. It comes with better interest rates, lower fees for money they haven’t used yet, better terms, and an extra A$105 million they can borrow if needed.
Q: What is PhotonAssay technology?
A: PhotonAssay is Chrysos Corporation’s flagship gold analysis technology. It replaces traditional fire assay with a faster, non-destructive, and more environmentally friendly method for analysing gold, silver, copper, and other elements in mining samples.
Disclaimer
The information contained in this article is general in nature and does not constitute financial product advice. Colitco and its contributors are not licensed financial advisers. This article does not take into account your personal financial situation, objectives, or needs. Before making any investment decision, you should consider obtaining independent financial advice from a licensed adviser. Past performance is not a reliable indicator of future performance. ASX-listed securities involve risk, including the possible loss of principal.
Source:
https://wcsecure.weblink.com.au/pdf/C79/03097126.pdf
Luke Carlino is a seasoned Copywriter, Content Strategist, and Social Media Manager specialising in Mining, Finance, and Business journalism. With more than a decade of industry experience, he brings rigorous editorial standards and commercial acuity to every project.
